Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-60 years old but no requirement for gender~2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic abnormal urinalysis~3. Informed consent is obtained from each research subject who agrees to conduct a periodic follow-up according to the research arrangement~Exclusion Criteria:~1. Secondary IgA nephropathy, such as Henoch-Schönlein purpura nephritis, Lupus nephritis and so on~2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis~3. Severe infection~4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or glutamic-oxal(o)acetic transaminase (GOT) more than twice upper limit of normal~5. Women during pregnancy and lactation~6. Patients need to procreation lately~7. Patients treated with TW or ARB within 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- immunosuppressor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).